Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. [electronic resource]
Producer: 20061030Description: 217-23 p. digitalISSN:- 0031-6970
- Administration, Oral
- Adult
- Area Under Curve
- Aryl Hydrocarbon Hydroxylases -- antagonists & inhibitors
- Blood Glucose -- metabolism
- Capsules
- Carbamates -- blood
- Chromatography, Liquid -- methods
- Cross-Over Studies
- Cytochrome P-450 CYP2C8
- Cytochrome P-450 CYP3A
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme System -- metabolism
- Drug Administration Schedule
- Enzyme Inhibitors -- blood
- Female
- Gas Chromatography-Mass Spectrometry -- methods
- Half-Life
- Humans
- Hypoglycemic Agents -- administration & dosage
- In Vitro Techniques
- Male
- Pioglitazone
- Piperidines -- blood
- Substrate Specificity
- Thiazolidinediones -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.